IFM 2026 opens in Dubai with 900+ primary-care professionals and 21 CME credits

The 13th International Family Medicine Conference & Exhibition opened at Dubai World Trade Centre on 25 August 2026, putting primary care, pharmacy-linked prevention and insurer-funded access at the centre of a three-day Dubai healthcare agenda.

The highest-stakes readers are clinic COOs, medical directors and insurer network heads. For Dubai clinics regulated by the Dubai Health Authority (DHA), the event is a live readout on where family medicine is moving: prevention, chronic-disease management, telemedicine, smart health tools and integration with pharmacy services. For Abu Dhabi and Al Ain operators, the same questions sit under the Department of Health Abu Dhabi (DOH). In Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, the relevant regulator is the Ministry of Health and Prevention (MOHAP).

What opened in Dubai

The conference runs from 25 to 27 August 2026 and brings together more than 900 professionals and participants from 10 countries, according to Big News Network, citing WAM. The scientific programme includes more than 45 speakers, over 18 scientific sessions, more than 70 scientific posters and eligibility for 21 CME credits.

Family medicine is more than the starting point of a patient's journey through the healthcare system; it is the foundation of community health. — Amb. Prof. Abdulsalam AlMadani, Chairman, IFM

IFM is organised by INDEX Conferences and Exhibitions Org., a member of INDEX Holding. The 2026 event is positioned around family medicine and healthcare system development. Its official site says the conference is a three-day programme for primary healthcare professionals in the Middle East and is accredited by DHA for the GCC region.

Why clinics and pharmacies should care

For clinic operators, the practical issue is service mix. Family medicine is where insurers, regulators and patients test whether outpatient networks can manage diabetes, hypertension, obesity, mental health, vaccination, screening and medication adherence before patients reach hospitals. A clinic that wants to make IFM commercially useful should leave with two lists: one for services it can launch under its current licence, and one for services that require regulator or payer approval.

• COOs should check whether new prevention, telemedicine or home-care workflows fit existing DHA, DOH or MOHAP facility licences.
• Medical directors should map the 21 CME credits against annual professional development requirements for family physicians, general practitioners, nurses and pharmacists.
• CFOs should ask each insurer which chronic-care pathways are reimbursed, bundled or excluded before pricing packages.
• Pharmacy leaders should verify whether medication therapy management, vaccination support or chronic refill services need added approvals in their emirate.

Price data is the weak point in most conference-led planning. UAE consultation fees, co-payments and pharmacy reimbursement depend on facility class, network tier and benefit design. Operators should verify tariffs through their payer contracts and patient-facing insurer apps. In Dubai, that means checking network rules for names such as Sukoon where contracted. In Abu Dhabi, Daman and Thiqa rules matter for many providers, but eligibility must be confirmed by member category and plan.

Insurer and patient implications

For insurers, the useful question is whether family medicine can reduce avoidable specialist and emergency use without creating extra claims volume. The IFM programme gives payer teams a place to test provider readiness. The commercial signal is strongest where clinics can show measurable follow-up: repeat HbA1c checks, blood-pressure control, vaccination completion, medication adherence and referral leakage.

For patients, the near-term effect is simpler. More trained family physicians and pharmacists can shift routine care into licensed outpatient settings closer to home. That only works when the provider is on the patient's insurance network and the service is covered. Patients should check three items before booking: the facility licence, the physician or pharmacist licence, and the insurer's co-payment or prior approval rule.

Dubai providers can verify licensed facilities through the DHA medical directory. Abu Dhabi and Al Ain operators can use DOH datasets published through Shafafiya. Northern Emirates providers should use the MOHAP medical facilities directory.

The next step for clinic and pharmacy owners is to compare IFM session themes with their licence scope, payer contracts and staffing plan before 27 August 2026. For market checks, readers can use the UAE Open Healthcare Directory to identify licensed pharmacy providers and compare provider coverage by emirate.